298
We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.
 a patient with type 2 diabetes mellitus: Subject; persistent hypoglycemia: Effect; the antitumor necrosis factor-alpha blocking agent etanercept: Treatment; previous insulin regimen: Treatment; type 2 diabetes mellitus: Treatment.Disorder; severe plaque psoriasis: Treatment.Disorder; etanercept: Treatment.Drug; insulin: Treatment.Drug; insulin: Combination.Drug; etanercept: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient with type 2 diabetes mellitus: Subject; persistent hypoglycemia: Effect; the antitumor necrosis factor-alpha blocking agent etanercept: Treatment; previous insulin regimen: Treatment; type 2 diabetes mellitus: Treatment.Disorder; severe plaque psoriasis: Treatment.Disorder; etanercept: Treatment.Drug; insulin: Treatment.Drug; insulin: Combination.Drug; etanercept: Combination.Drug